Novo Nordisk’s haemophilia A drug stops bleeds in 74% of children
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/19.CcrFU5Zy.js ...
FierceBiotech1d
Novo Nordisk adds pediatric data to bulging bag of evidence on near-approval hemophilia A prospect
Novo Nordisk has bolstered the case for its near-approval hemophilia A drug candidate Mim8, linking the prospect to ...
PMLiVE1d
Novo Nordisk’s haemophilia A therapy Mim8 shows promise in late-stage study
Novo Nordisk has shared positive results from a late-stage study of its investigational haemophilia A therapy Mim8 in ...
Novo Nordisk reports interim results from late-stage trial of its haemophilia A treatment
Novo Nordisk announced interim results from the phase 3 FRONTIER3 trial of 70 children (aged 1-11 years old) with haemophilia ...
The Pharma Letter1d
Novo Nordisk adds to Mim8 data set ahead of filing
Danish pharma major Novo Nordisk has announced interim results from the Phase III FRONTIER3 trial of 70 children with ...
BioSpace22h
Novo’s Bispecific for Hemophilia Aces Phase III Pediatric Trial
Novo Nordisk’s bispecific antibody Mim8 prevented bleeding events and caused no adverse safety events in the Phase III FRONTIER3 trial. The company plans to file for approval this year, hoping to ...
Novo Nordisk A/S: Once-weekly Mim8 is well-tolerated and efficacious in children living with haemophilia A with and without inhibitors
Phase 3 FRONTIER3 interim analysis data presented at EAHAD 2025 showed that 74.3% of children on once-weekly Mim8 prophylaxis experienced zero treated bleeds Bagsværd, Denmark, 7 February 2025 – Novo ...
The Motley Fool6d
Forget Wegovy: Novo Nordisk May Have a New Billion-Dollar Weight Loss Drug On Its Hands
Novo Nordisk reported strong data for its next-gen anti-obesity medicine. The Danish company has an excellent weight loss drug pipeline. But it's also diversifying its lineup and offering other perks.
PipelineReview.com1d
Once-weekly Mim8 is well-tolerated and efficacious in children living with haemophilia A with and without inhibitors
Phase 3 FRONTIER3 interim analysis data presented at EAHAD 2025 showed that 74.3% of children on once-weekly Mim8 prophylaxis experienced zero treated ...